English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Manage 2015;61:28-33. 10. Khodosovskiĭ MN, Zinchuk VV. Erythropoietin influence on the blood oxygen transport and prooxidant-antioxidant state during hepatic ischemia-reperfusion. Ross Fiziol Zh Im I M Sechenova 2014;100:592-601. 11. Kalantzi M, Kalliakmani P, Papachristou E, et al. Parameters influencing blood erythropoietin levels of renal transplant recipients during the early post-transplantation period. Transplant Proc 2014;46:3179-82. 12. Hernández-Navarrete LS, Hernández-Jiménez JD, JiménezLópez LA, Budar-Fernández LF, Méndez-López MT, MartínezMier G. Experience in kidney transplantation without blood transfusion: kidney transplantation transfusion-free in Jehovah's Witnesses. First communication in Mexico. Cir Cir 2013;81: 450-3. 13. Zabaneh R, Roger SD, El-Shahawy M, et al. Peginesatide to manage anemia in chronic kidney disease patients on peritoneal dialysis. Perit Dial Int 2015;35:481-9. 14. Bartnicki P, Kowalczyk M, Rysz J. The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection. Med Sci Monit 2013;19:599-605. 15. Tsompos C, Panoulis C, Toutouzas K, Triantafyllou A, Zografos GC, Papalois A. Comparison of the attenuating capacities of erythropoietin and U-74389G concerning blood platelet counts. J Sci Achiev 2017;2:18-21.

Low-dose prednisolone in patients with paroxysmal nocturnal hemoglobinuria and inadequate response to eculizumab